A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

Inclusion Criteria: * Males or Females * Aged from 18 to 75 years * New York Heart Association(NYHA) classification Ⅱ-Ⅲ * At screening, subject has an LVEF\<0.45 * Have received optimal therapy with an Angiotensin converting enzyme inhibitors or angiotensin receptor blocker for 4 weeks before enrollment * Subjects with symptoms of Stable heart failure do not need intravenous injection diuretics,cardiac inotropes or vasodilators * Willing to provide written informed consent Exclusion Criteria: * Current treatment on any Class I or III antiarrhythmic, except amiodarone or beta-blockers * Current treatment on calcium antagonists except for long-acting dihydropyridine agents * Have a history of acute coronary syndrome,cerebral apoplexy or transient ischemic attack with 3 months * Have a history of cardio-vascular surgery or other vessel operations with 3 months * Have a history of sustained ventricular tachycardia or ventricular fibrillation with 3 months * Have a plan to receive coronary revascularization or heart transplantation * Uncontrolled ventricular arrhythmias (not controlled with antiarrhythmic therapy or an implantable defibrillator) * Subjects with uncorrected primary obstructive or severe regurgitative valvular disease，nondilated (restrictive) or hypertrophic cardiomyopathy * Sitting systolic blood pressure≤90mmHg (based on an average of 3 readings) * Current decompensated heart failure * Second or third degree heart block，or sick sinus syndrome，a pacemaker is not placed * Contraindication to vasodilators * Have a history of cardiac resynchronization therapy or * Have received cardioverter defibrillator or pacemaker with 1 month * Resting heart rate\<50 beats per minute(based on the average of 3 readings) * Elevated liver enzymes (alanine aminotransferase or aspartate aminotransferase levels greater than 3 times upper limit of normal) * Serum creatinine levels greater than 2 times upper limit of normal * Current clinical evidence of obstructive pulmonary disease (e.g., asthma or bronchitis) requiring inhaled or oral bronchodilator or steroid therapy * History of drug sensitivity or allergic reaction to alpha or beta-blockers * Contraindication or intolerance to beta-blockers * Pregnant or lactating women and women planning to become pregnant * Has any systemic disease, including cancer, with reduced life expectancy (\<12 months) * Use of an investigational drug within 30 days of enrollment * Participation in an investigational device trial within 30 days of enrollment * Known drug or alcohol abuse 1 year prior to enrollment * Has a history of psychological illness/condition that interferes with ability to understand or complete requirements of the study * In the opinion of the investigator the subject is known to be noncompliant with prescribed medication regimen